Glenmark Pharmaceuticals Ltd Q1FY22 consolidated PAT at Rs. 306.52 crores

Glenmark Pharmaceuticals ltd has reported financial results for the period ended June 30, 2021.

Financial Results (Q1 FY 2021-22) - QoQ Comparison

The company has reported total income of Rs.3023.54 crores during the period ended June 30, 2021 as compared to Rs.2868.39 crores during the period ended March 31, 2021.

The company has posted net profit / (loss) of Rs.306.52 crores for the period ended June 30, 2021 as against net profit / (loss) of Rs.233.87 crores for the period ended March 31, 2021.

The company has reported EPS of Rs.10.86 for the period ended June 30, 2021 as compared to Rs.8.29 for the period ended March 31, 2021.

Financials	Q1 FY2021-22	Q4 FY20-21	% Change
Total Income	₹ 3023.54 crs	₹ 2868.39 crs	5.41%
Net Profit	₹ 306.52 crs	₹ 233.87 crs	31.06%
EPS	₹ 10.86	₹ 8.29	31%

Financial Results (Q1 FY 2021-22) - YoY Comparison

The company has reported total income of Rs.3023.54 crores during the period ended June 30, 2021 as compared to Rs.2403.30 crores during the period ended June 30, 2020.

The company has posted net profit / (loss) of Rs.306.52 crores for the period ended June 30, 2021 as against net profit / (loss) of Rs.254.04 crores for the period ended June 30, 2020.

The company has reported EPS of Rs.10.86 for the period ended June 30, 2021 as compared to Rs.9 for the period ended June 30, 2020.

Financials	Q1 FY2021-22	Q1 FY2020-21	% Change
Total Income	₹ 3023.54 crs	₹ 2403.30 crs	25.81%
Net Profit	₹ 306.52 crs	₹ 254.04 crs	20.66%
EPS	₹ 10.86	₹ 9	20.67%

Shares of Glenmark Pharmaceuticals ltd was last trading in BSE at Rs. 563.2 as compared to the previous close of Rs. 570.8. The total number of shares traded during the day was 168071 in over 6723 trades.

The stock hit an intraday high of Rs. 575.8 and intraday low of 560.2. The net turnover during the day was Rs. 95351887.

Source : Equity Bulls

Keywords